Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

What are the percentages that the company goes

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
mrmainstreet Member Profile
 
Followed By 15
Posts 3,297
Boards Moderated 0
Alias Born 03/25/13
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:25:35 PM
Amarin Honored by BioNJ with Innovator Award for VASCEPA® Development and Regulatory Approval GlobeNewswire Inc. - 2/6/2020 9:26:23 PM
Amarin Launches True To Your Heart, a Campaign to Educate People on Persistent Cardiovascular Risk GlobeNewswire Inc. - 1/13/2020 6:00:10 AM
Amarin Provides Update to Preliminary 2019 Results and Further Details on 2020 Outlook GlobeNewswire Inc. - 1/7/2020 6:00:10 AM
Amarin to Present at 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire Inc. - 1/6/2020 6:00:10 AM
VASCEPA® Approved in Canada to Reduce the Risk of Cardiovascular Events GlobeNewswire Inc. - 1/2/2020 6:00:10 AM
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk PR Newswire (US) - 12/13/2019 6:14:00 PM
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk GlobeNewswire Inc. - 12/13/2019 4:49:07 PM
European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) f... GlobeNewswire Inc. - 12/2/2019 6:00:10 AM
Amarin Highlights Key REDUCE-IT®-Related Data Presented at American Heart Association 2019 Scientific Sessions GlobeNewswire Inc. - 11/18/2019 5:30:00 PM
Amarin’s John Thero Awarded EY Entrepreneur of The Year® 2019 Life Sciences National Award GlobeNewswire Inc. - 11/18/2019 12:15:12 PM
Amarin Announced FDA Advisory Committee Voted Unanimously (16-0) to Recommend Approval of Vascepa® (icosapent ethyl) Capsule... GlobeNewswire Inc. - 11/14/2019 5:34:37 PM
Amarin Corporation plc (NASDAQ:AMRN) Stock Trading Halted Today for Scheduled FDA Advisory Committee Review of sNDA Seeking N... GlobeNewswire Inc. - 11/14/2019 6:59:25 AM
New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthca... GlobeNewswire Inc. - 11/11/2019 1:19:57 PM
REDUCE-IT® USA Results, in Prespecified Subgroup Analyses of Landmark REDUCE-IT Global Study, Showed Robust Cardiovascular R... GlobeNewswire Inc. - 11/11/2019 6:30:48 AM
Amarin to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire Inc. - 11/11/2019 5:00:00 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/5/2019 5:29:19 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 6:37:28 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 6:31:38 AM
Amarin Reports Third Quarter 2019 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 11/5/2019 5:00:00 AM
Seven Data Presentations Relevant to Vascepa® (Icosapent Ethyl) Capsules and Persistent Cardiovascular Risk to be Presented ... GlobeNewswire Inc. - 11/4/2019 6:00:00 AM
Amarin to Report Third Quarter 2019 Results and Host Conference Call on November 5, 2019 GlobeNewswire Inc. - 10/24/2019 4:30:05 PM
On Watch this Week with Near-Term Potential Catalysts InvestorsHub NewsWire - 10/21/2019 8:00:00 AM
Independent Drug-Pricing Assessment Finds Vascepa® (icosapent ethyl) Cost-Effective as an Adjunct to Statins in Treating Pat... GlobeNewswire Inc. - 10/17/2019 9:49:02 AM
Amarin to Participate in the Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/23/2019 4:15:00 PM
mrmainstreet   Saturday, 11/30/19 01:12:05 AM
Re: None
Post # of 246817 
What are the percentages that the company goes it alone vs. gets acquired?

If it gets acquired what are the percentages the purchase price is $16B or more?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist